Endocrine Abstracts

Background: Lu177 DOTATATE Peptide Receptor Radionucleotide Therapy (PRRT) was FDA approved in the United States in 2018, however, the data for the safety and efficacy of repeat PRRT are almost exclusively from European centers. We present an updated experience with repeat PRRT in a cohort of US patients.Methods: We used our single-center longitudinal IRB approved neuroendocrine tumor (NET) registry to identify patients who had been previously treated wi...